A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen
A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Genzyme, a Sanofi Company, completed.
Overview
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen is a phase 3 interventional study registered as NCT00295763 by Genzyme, a Sanofi Company, with 61 participants recorded, started 2006-05 and reaching its primary completion in 2006-07. Interventions recorded: Thyrogen (thyrotropin alfa for injection). Conditions recorded: Differentiated Thyroid Cancer.
Linked to the drug Thyrotropin alfa because the registry names it among its interventions and Thyroid cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialrhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)
Shares Thyrotropin alfa, Thyroid cancer and the tag pipeline.
- TrialComparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Shares Thyrotropin alfa, Thyroid cancer and the tag pipeline.
- TrialMobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Shares Sanofi and the tag pipeline.
- TrialA Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
Shares Sanofi and the tag pipeline.
- TrialTwo Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
Shares Sanofi and the tag pipeline.
- TrialSAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Shares Sanofi and the tag pipeline.
- TrialTusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Shares Sanofi and the tag pipeline.
- TrialEvaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Shares Sanofi and the tag pipeline.